

1 **Is Second dose of vaccination useful in previously SARS-CoV-2 infected Health Care**  
2 **Workers?**

3 **Gauthier PEAN DE PONFILLY<sup>1,2</sup>, Benoît PILMIS<sup>2,4</sup>, Iheb EL KAIBI<sup>3</sup>, Nathalie CASTREAU<sup>5</sup>,**  
4 **Sophie LAPLANCHE<sup>3</sup>, and Alban LE MONNIER<sup>1,2\*</sup>**

5 1. Service de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France

6 2. Institut Micalis UMR 1319, Université Paris-Saclay, INRAe, AgroParisTech, Châtenay  
7 Malabry, France

8 3. Laboratoire de Biologie Médicale, Groupe Hospitalier Saint-Joseph, Paris, France

9 4. Équipe Mobile de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris,  
10 France

11 5. Service de santé au travail, Groupe Hospitalier Paris Saint-Joseph, Paris, France  
12

13

14 **Summary**

15

16 Vaccines are the most important public health measure to protect people from COVID-19  
17 worldwide. In addition, healthcare workers account for a large number of infected people.  
18 Then, protecting this population from COVID-19 seems crucial in the preservation of  
19 healthcare systems. In a context of few doses available, serological assays could be useful to  
20 decide whether one or two doses are needed. Our results show that a first dose of BNT162b2  
21 mRNA vaccine seems to act as a boost after SARS-CoV-2 infection in healthcare workers with  
22 a previous SARS-CoV-2 infection and a second dose might not be required.

23

24

25

26 **\* Corresponding author:**

27 Prof. Alban Le Monnier

28 Service de Microbiologie clinique

29 Groupe Hospitalier Paris Saint-Joseph

30 185 rue Raymond Losserand, 75014, Paris, France

31 Tel: +33 1 44 12 79 32 Fax: + 33 1 44 12 35 13

32 Mail: [alemonnier@ghpsj.fr](mailto:alemonnier@ghpsj.fr)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 33 **Introduction**

34 Since the early 2020, a large pandemic due to the new and emergent coronavirus (SARS-CoV-  
35 2) spreads all over the world. While some countries have been able to contain the pandemic  
36 with a combination of public health measures (extensive testing followed by isolation and  
37 tracing of contacts, near-universal masking, and target quarantines), most countries have  
38 failed to stop the pandemic. Much hope now resides in the potential of SARS-CoV-2 vaccines  
39 to reduce the risk of disease and infection. Strategies aimed to maximize the early impact of  
40 vaccination in a context of few doses available [1]. As soon as early January 2021, large  
41 vaccination campaign started in France first for populations at risk of severe COVID-19 but  
42 rapidly also for Healthcare workers (HCWs) more than 50 years or with underlying disease,  
43 then for all voluntary HCWs. Indeed, numerous studies have underlined the risk of nosocomial  
44 transmission to and from healthcare workers in hospital settings [2,3].

45 Then, the issue of vaccination of patients and HCWs with a history of recent or late SARS-CoV-  
46 2 related infection has become a major issue to reduce this risk. Currently, French guidelines  
47 recommends vaccination in those cohort that are recovered from COVID-19 since six months  
48 and to offer them only one dose [4]. Moreover, serological assays are not included in the  
49 decision-making strategy of vaccination.

50 We aimed to provide data on immune response induced by SARS-CoV-2 vaccines in real world  
51 context that can support this choice. Here, we reported kinetics of production of antibodies  
52 directed to the Spike protein of SARS CoV-2 after first, then second vaccine dose (conventional  
53 prime-boost strategy recommended) in Health Care Workers.

54

## 55 **Material and methods**

56 All HCWs currently working at the Groupe Hospitalier Paris Saint-Joseph (Paris, France) and  
57 eligible to vaccination were proposed to be included in an observational cohort study after  
58 first then second dose of the BNT162b2 mRNA COVID-19 vaccine (Pfizer / BioNTech, Mainz,  
59 Germany).

60 They were divided in two groups: HCWs with a previous history of SARS-Cov-2 infection  
61 (COVID-19 (+)) and HCWs with no history of SARS-Cov-2 infection (COVID-19 (-)) according to

62 the result of RT-PCR and/or serology to confirm previous contact with SARS-CoV-2. Minimal  
63 information were collected like sex, age, dates of first and second vaccine doses.

64 After agreement, HCWs have first serology 28 days after the first dose before receiving the  
65 second dose, then a second serology 21 to 28 days after.

66 HCWs with a history of COVID-19 came from the ongoing PERSOCOVID longitudinal  
67 observational cohort study. Briefly, these colleagues have benefited of a longitudinal  
68 serological follow-up since the onset of the disease. For each of them, the level of antibodies  
69 directed to Spike protein before vaccination was known. No COVID-19 recently diagnosed in  
70 the last three months were included in the study, according to French health agencies  
71 recommendations.

72 Serological assays used the quantitative test (SARS-CoV-2 IgG II Quant, Architect System,  
73 Abbott) for detecting serum antibodies directed to receptor-binding domain (RBD) of the  
74 Spike-1 protein of SARS-CoV-2. Quantitative results are converted in AU/mL. Dilution was  
75 performed for each result beyond 40,000 AU/mL according to the manufacturer's instructions.  
76 The positivity threshold was 50 AU/mL according to manufacturer's instructions.

77 For the statistical comparison, a Shapiro-Wilk test for normality of distribution was first  
78 performed and a t-student test was performed for continuous variables, using the R software  
79 version 3.1.3[4]. Significance was considered if  $p < 0.05$ .

80

## 81 **Results**

82 Seventy-three HCWs gave consent to participated to this study and distributed in 29 (39.7%)  
83 COVID-19 (+) and 44 (60.3%) COVID-19 (-). No case of severe COVID-19 was recruited in this  
84 study and median [IQR] age of the included HCWs was 43.5 [34 – 56.5] years old. The median  
85 time from first dose to serology was 25 days and 28 days from second dose to second serology.  
86 We first reported a significant difference in anti-Spike antibody levels (median [IQR]) around  
87 46-fold higher in COVID-19 (+) (28111 [15032-33967] AU/mL) than in COVID-19 (-) (642 [338-  
88 1170] AU/mL) ( $p < 0.001$ ) after the first dose. Antibody levels produced after the first dose in  
89 COVID-19 (-) are quite similar than those observed in COVID-19 (+) (324 [116-630] AU/mL) not  
90 yet vaccinated. In the latter, the antibody levels increased on a mean by 88-fold after the first  
91 vaccine dose.

92 After the first vaccine dose, COVID-19 (-) presented a median level of IgG anti-Spike at 617  
93 [338-1147] AU/mL and their median level increases significantly 28 days after their second  
94 dose at 9711 [4978-15473] AU/mL ( $p < 0.001$ ). Previous infection seemed to be analogous to  
95 natural immune priming.

96 After the second dose, COVID-19 (-) significantly increased their antibody levels (10491  
97 [5341-16193] AU/mL) without, however, reaching the levels generally observed for COVID-  
98 19 (+) after a single dose. For COVID-19 (+), we observed that the second dose did not  
99 significantly increase their antibody level (35459 [11565-38500] AU/mL;  $p=0.18$ ).

100

## 101 **Discussion**

102 Following a single dose of BNT162b2, HCWs with a previous SARS-CoV-2 infection have  
103 significantly higher antibody response than naive HCWs. The first dose of the vaccine seems  
104 to act as a boost after SARS-CoV-2 infection and a second dose might not be required in case  
105 of previous SARS-CoV-2 infections.

106 A delayed booster beyond the 30 days initially recommended for the BNT162b2/Pfizer vaccine  
107 could then be proposed. This is an important element in the current context of few doses  
108 available to accelerate vaccine rollout [1].

109 Furthermore, COVID-19 is associated with an increase in HCWs absenteeism making the  
110 management of a public health crisis even more complicated [5].

111 However, we also reported a paradoxically lower response than those expected for one  
112 COVID-19 (+). This HCW presented a positive RT-PCR and a positive serological assay  
113 confirming previous contact with SARS-CoV-2. This suggests that the use of serological tests  
114 could be useful to confirm adequate vaccine response without, however, the correlate of  
115 protection value. Indeed, here no neutralization assays have been carried out because they  
116 are difficult to set up on a routine basis [6]. For HCWs with a previous SARS-CoV-2 infection, a  
117 determination of the antibodies level produced after the first dose can be proposed just  
118 before the second dose to decide whether or not it is necessary.

119 Kinetics of natural anti-Spike antibody levels decrease more or less rapidly according to initial  
120 level of IgG produced. In some cases, anti-Spike antibodies become undetectable beyond six

121 or eight months for some HCWS or some patients [7,8]. This also raises the question of the  
122 durability of the antibodies produced either after prime or boosted vaccination as for COVID-  
123 19 course and the impact of high initial antibodies levels.

124 Our study provides additional information on the positioning and usefulness of serology in the  
125 COVID-19 vaccine strategy in order to maximize coverage and impact.

126

## 127 **Acknowledgement:**

128 We thank all colleagues who accept to participate to this study, in particular staff of the  
129 Occupational Medicine Department: Morgane PAUILLAT, Mathilde HERR, Dr Priscilla SAVIN,  
130 and Dr Patricia MALARDY.

131

## 132 **References**

- 133 [1] Henn W. Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and  
134 necessary measures for global immunity. *Vaccine* 2020;38:5396–7.  
135 <https://doi.org/10.1016/j.vaccine.2020.06.058>.
- 136 [2] Abbas M, Robalo Nunes T, Martischang R, Zingg W, Iten A, Pittet D, et al. Nosocomial  
137 transmission and outbreaks of coronavirus disease 2019: the need to protect both  
138 patients and healthcare workers. *Antimicrob Resist Infect Control* 2021;10:7.  
139 <https://doi.org/10.1186/s13756-020-00875-7>.
- 140 [3] Schwierzeck V, König JC, Kühn J, Mellmann A, Correa-Martínez CL, Omran H, et al. First  
141 Reported Nosocomial Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 in  
142 a Pediatric Dialysis Unit. *Clin Infect Dis Off Publ Infect Dis Soc Am* 2021;72:265–70.  
143 <https://doi.org/10.1093/cid/ciaa491>.
- 144 [4] HAS. Stratégie de vaccination contre le SARS-CoV-2 : Vaccination des personnes ayant un  
145 antécédent de Covid-19. 11/02/2021 n.d.
- 146 [5] Groenewold MR, Burrer SL, Ahmed F, Uzicanin A, Free H, Luckhaupt SE. Increases in  
147 Health-Related Workplace Absenteeism Among Workers in Essential Critical  
148 Infrastructure Occupations During the COVID-19 Pandemic — United States, March–April  
149 2020. *Morb Mortal Wkly Rep* 2020;69:853–8.  
150 <https://doi.org/10.15585/mmwr.mm6927a1>.
- 151 [6] Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, et al. COVID-19-  
152 neutralizing antibodies predict disease severity and survival. *Cell* 2021;184:476-488.e11.  
153 <https://doi.org/10.1016/j.cell.2020.12.015>.
- 154 [7] Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to  
155 SARS-CoV-2 assessed for up to 8 months after infection. *Science* 2021.  
156 <https://doi.org/10.1126/science.abf4063>.


157 [8] Marot S, Malet I, Leducq V, Zafilaza K, Sterlin D, Planas D, et al. Rapid decline of  
158 neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. *Nat*  
159 *Commun* 2021;12. <https://doi.org/10.1038/s41467-021-21111-9>.

160

161

162

163



164 **Figure 1.** Evolution of anti-Spike IgG titer expressed in log<sub>10</sub> AU/mL during the vaccination  
165 protocol, according to history of COVID-19.